BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Humira (adalimumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Humira (adalimumab)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05874505-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT05874505)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: "Comparison of the Effic
 acy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of B
 ehçet's Disease"\nEstimated primary completion: November 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05874505
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398651-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Humira (adalimumab): Phase na readout est. (NCT07398651)
DESCRIPTION:Humira (adalimumab)\, phase na\, Psoriatic Arthritis.\nStudy: A
 premilast and Adalimumab in Psoriatic Arthritis Patients\nEstimated primar
 y completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07398651
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05105347-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT05105347)
DESCRIPTION:Humira (adalimumab)\, phase 4.\nStudy: Efficacy and Safety of A
 dalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet
 's Uveitis\nEstimated primary completion: 31 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05105347
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03153319-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Humira (adalimumab): Phase 1/2 readout est. (NCT03153319)
DESCRIPTION:Humira (adalimumab)\, phase 1/2.\nStudy: Study to Evaluate the 
 Safety and Efficacy of Adalimumab in MPS I\, II\, and VI\nEstimated primar
 y completion: January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/adalimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03153319
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Humira (adalimumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Humira (adalimumab)\, phase 2/3.\nStudy: Using a Contact Dermat
 itis Model With Biologic Medications to Study Skin Inflammation\nEstimated
  primary completion: 1 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05590455-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT05590455)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: Tnf Inhibitors to Reduce
  Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis\nEstima
 ted primary completion: June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05590455
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926478-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Humira (adalimumab): Phase 1 readout est. (NCT06926478)
DESCRIPTION:Humira (adalimumab)\, phase 1.\nStudy: Subconjunctival Humira f
 or Boston Keratoprosthesis\nEstimated primary completion: 1 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06926478
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258915-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Humira (adalimumab): Phase 3 readout est. (NCT06258915)
DESCRIPTION:Humira (adalimumab)\, phase 3\, Non-Infectious Uveitis.\nStudy:
  Treatment FOr Corticosteroid Dependent UveitiS\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ada
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06258915
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045754-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT06045754)
DESCRIPTION:Humira (adalimumab)\, phase 4\, Crohn's Disease.\nStudy: A Stud
 y of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Usteki
 numab in Adults With Crohn's Disease\nEstimated primary completion: 28 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/adalimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT060457
 54
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849908-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06849908)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: Baricitinib in the Treat
 ment of Intestinal Behçet's Syndrome\nEstimated primary completion: 30 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/adalimumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06849
 908
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941376-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06941376)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: Pragmatic\, Open-Label S
 tudy to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis\n
 Estimated primary completion: July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06941376
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05928039-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT05928039)
DESCRIPTION:Humira (adalimumab)\, phase 4\, Crohn's Disease.\nStudy: PATHFI
 NDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to
 -Severely Active Ileal-dominant Crohn's Disease\nEstimated primary complet
 ion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ad
 alimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05928039
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06833112-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT06833112)
DESCRIPTION:Humira (adalimumab)\, phase 4.\nStudy: Interleukin-17 (IL-17) I
 nhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor fo
 r the Treatment of Ankylosing Spondylitis\nEstimated primary completion: A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adalimuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 833112
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06257875-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06257875)
DESCRIPTION:Humira (adalimumab)\, phase 2\, Ulcerative Colitis.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity From Intraven
 ous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Acti
 ve Ulcerative Colitis\nEstimated primary completion: September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06257875
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180382-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT06180382)
DESCRIPTION:Humira (adalimumab)\, phase 4\, Crohn's Disease.\nStudy: Compar
 ison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn'
 s Disease Patients With Loss of Response or Biomarker Activity to Adalimum
 ab on First Line With Therapeutic Drug Concentration.\nEstimated primary c
 ompletion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/adalimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06180382
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06037811-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06037811)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: Early Adalimumab Inducti
 on for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06037811
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491913-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Humira (adalimumab): Phase na readout est. (NCT07491913)
DESCRIPTION:Humira (adalimumab)\, phase na.\nStudy: Biologic Treatment With
 drawal in Takayasu Arteritis Patients in Sustained Remission\nEstimated pr
 imary completion: 15 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07491913
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258641-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Humira (adalimumab): Phase 1/2 readout est. (NCT07258641)
DESCRIPTION:Humira (adalimumab)\, phase 1/2\, Ulcerative Colitis.\nStudy: F
 luorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflamma
 tory Bowel Disease\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07258641
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440629-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT06440629)
DESCRIPTION:Humira (adalimumab)\, phase 4\, Rheumatoid Arthritis.\nStudy: E
 ffect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained
  Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF
  Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA
 -DRUM)\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adalimumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06440629
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Humira (adalimumab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Humira (adalimumab)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07529925-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT07529925)
DESCRIPTION:Humira (adalimumab)\, phase 4\, Psoriasis.\nStudy: A Clinical T
 rail of Adalimumab in Treating Chinese Children With Severe Plaque Psorias
 is\nEstimated primary completion: April 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07529925
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062875-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06062875)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: Effects of TNF Blockade 
 on Human BPH/LUTS\nEstimated primary completion: 1 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06062875
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510191-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT07510191)
DESCRIPTION:Humira (adalimumab)\, phase 4\, Crohn's Disease.\nStudy: TNFi P
 lus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With 
 Suboptimal Response\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07510191
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913750-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Humira (adalimumab): Phase na readout est. (NCT07913750)
DESCRIPTION:Humira (adalimumab)\, phase na.\nStudy: Efficacy and Safety of 
 Adalimumab for the Treatment of Ocular Inflammation\nEstimated primary com
 pletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/adalimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07913750
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996652-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06996652)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: An Exploratory Study of 
 the Potential for Rational Immune System Manipulation to Prevent Emergence
  of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Diso
 rder (RBD)\nEstimated primary completion: 1 August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/adalimumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06996652
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268534-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT07268534)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: Biologics in Folliculiti
 s Decalvans : an Adaptative Trial Research\nEstimated primary completion: 
 1 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adal
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07268534
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904780-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20291111
DTEND;VALUE=DATE:20291112
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT07904780)
DESCRIPTION:Humira (adalimumab)\, phase 4.\nStudy: Withdrawal Versus Contin
 ued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile
  Idiopathic Arthritis\nEstimated primary completion: 11 November 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07904780
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390436-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT06390436)
DESCRIPTION:Humira (adalimumab)\, phase 4.\nStudy: Therapeutic Drug Monitor
 ing-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis\nEsti
 mated primary completion: December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06390436
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061574-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20300415
DTEND;VALUE=DATE:20300416
SUMMARY:Humira (adalimumab): Phase 1/2 readout est. (NCT07061574)
DESCRIPTION:Humira (adalimumab)\, phase 1/2.\nStudy: A Randomized Phase 1/2
  Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimuma
 b or Verapamil in New Onset Type 1 Diabetes\nEstimated primary completion:
  15 April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adali
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07061574
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699107-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT07699107)
DESCRIPTION:Humira (adalimumab)\, phase 4.\nStudy: Adalimumab Dose Adjustme
 nt for Pediatric Uveitis Treatment Trial\nEstimated primary completion: Ma
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/adalimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076991
 07
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Humira (adalimumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Humira (adalimumab)\, phase 4\, Psoriasis.\nStudy: Utilization 
 of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary co
 mpletion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/adalimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07352566
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845604-8@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT07845604)
DESCRIPTION:Humira (adalimumab)\, phase 2.\nStudy: Precision Depression Ada
 limumab Trial\nEstimated primary completion: July 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adalimumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07845604
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
